Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576866 | 0.88 | KMT2A (0.47) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL28137098 | 0.81 | MEN1 (0.44) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL1577179 | 0.81 | MEN1 (0.44) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL1576811 | 0.79 | ALOX5 (0.46) | KMT2AMEN1NPC1RAB9ACA9 | |
| SCHEMBL6813227 | 0.78 | KMT2A (0.54) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL1576833 | 0.78 | MEN1 (0.41) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL25342645 | 0.76 | EPHX1 (0.50) | KMT2AMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL25342640 | 0.76 | EPHX1 (0.50) | KMT2AMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL3368953 | 0.76 | KMT2A (0.51) | KMT2AMEN1NPC1RAB9ACA12 | |
| SCHEMBL900942 | 0.75 | ADRA2B (0.54) | KMT2AMEN1NPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533345-B2 | Rufinamide for use in the treatment of myotonia | AARHUS UNIVERSITET (DK) | 2026-01-27 | — | — | US | disclosed |
| US-20240307357-A1 | RUFINAMIDE FOR USE IN THE TREATMENT OF MYOTONIA | AARHUS UNIVERSITET (DK) | 2024-09-19 | — | — | US | disclosed |
| US-12023322-B2 | Rufinamide for use in the treatment of myotonia | AARHUS UNIVERSITET (DK) | 2024-07-02 | — | — | US | disclosed |
| US-11278502-B2 | Modified release formulation of lacosamide | LUPIN LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
| US-10786464-B2 | Modified release formulation of lacosamide | LUPIN LIMITED (IN) | 2020-09-29 | — | — | US | disclosed |
| EP-2496220-B1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | LUPIN LTD (IN) | 2019-10-16 | — | — | EP | disclosed |
| US-20190029968-A1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | LUPIN LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
| EP-2496220-A1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | Lupin Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120219631-A1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | LUPIN LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| WO-2011055385-A1 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | LUPIN LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307357-A1 | RUFINAMIDE FOR USE IN THE TREATMENT OF MYOTONIA | MYOF, CKMT1A; CKMT1B, MTPN | KMT2A 383/4885MEN1 1829/4885NPC1 4559/4885 |
| US-12533345-B2 | Rufinamide for use in the treatment of myotonia | CKMT1A; CKMT1B, CPT1B, MYLK2 | KMT2A 228/4885MEN1 2305/4885NPC1 3241/4885 |
| US-12023322-B2 | Rufinamide for use in the treatment of myotonia | MYOF, CKMT1A; CKMT1B, MTPN | KMT2A 287/4885MEN1 1864/4885NPC1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.